Download PDF
Semin Thromb Hemost 2013; 39(01): 094-100
DOI: 10.1055/s-0032-1331154
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bleeding Complications in Patients with Hematologic Malignancies

Massimo Franchini
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
,
Francesco Frattini
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
,
Silvia Crestani
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
,
Carlo Bonfanti
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
17 December 2012 (online)

    Permissions and Reprints

Abstract

Abnormalities of hemostasis are frequently encountered in patients with hematologic malignancies leading to both hemorrhagic and thrombotic adverse events. The prompt recognition and management of such complications, which have a negative impact on the morbidity and mortality of these patients, represents a major challenge for hematologists. This review describes the most important changes of hemostasis associated with hemorrhage in hematologic malignancies with particular emphasis on their contributory etiologic factors, complex pathogenic mechanisms, clinical manifestations, and therapeutic strategies. In particular, platelet and acquired coagulation abnormalities, bleeding complications in acute leukemia, and hematopoietic stem cell transplantation are discussed.

Keywords

bleeding - leukemia - hematologic malignancies - therapy
 

  • References

  • 1 Trousseau A. Phlegmasia alba dolens. In: Trousseau A, , ed. Clinique Medicinale de l'Hotel-Dieu de Paris. Paris, France: JB Bailliere et fils; 1865: 645-712
    Google Scholar
  • 2 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24 (1) 29-38
    CrossrefPubMedGoogle Scholar
  • 3 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 2012; 38 (1) 95-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18 (4) 353-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996; 10 (4) 875-907
    CrossrefPubMedGoogle Scholar
  • 6 Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?. Thromb Res 2007; 120 (Suppl. 02) S99-S106
    CrossrefPubMedGoogle Scholar
  • 7 Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 427-434
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Carlson KS, DeSancho MT. Hematological issues in critically ill patients with cancer. Crit Care Clin 2010; 26 (1) 107-132
    CrossrefPubMedGoogle Scholar
  • 9 Athale UH, Chan AKC. Hemorrhagic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 408-415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18 (3) 153-167
    CrossrefPubMedGoogle Scholar
  • 11 Slichter SJ. Evidence based platelet transfusion guidelines. Hematology (Am Soc Hematol Educ Program) 2007; 172-178
    PubMedGoogle Scholar
  • 12 Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15 (3) 1143-1149
    PubMedGoogle Scholar
  • 13 Rebulla P, Finazzi G, Marangoni F , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337 (26) 1870-1875
    CrossrefPubMedGoogle Scholar
  • 14 Zumberg MS, del Rosario ML, Nejame CF , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002; 8 (10) 569-576
    CrossrefPubMedGoogle Scholar
  • 15 Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005; 45 (7) 1064-1072
    CrossrefPubMedGoogle Scholar
  • 16 Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21 (4) 697-729 , vii
    CrossrefPubMedGoogle Scholar
  • 17 Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them?. Br J Haematol 2011; 154 (4) 425-440
    CrossrefPubMedGoogle Scholar
  • 18 British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122 (1) 10-23
    CrossrefPubMedGoogle Scholar
  • 19 Slichter SJ, Kaufman RM, Assmann SF , et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362 (7) 600-613
    CrossrefPubMedGoogle Scholar
  • 20 Estcourt LJ, Stanworth SJ, Murphy MF. Prophylactic platelet transfusions. Curr Opin Hematol 2010; 17 (5) 411-417
    CrossrefPubMedGoogle Scholar
  • 21 Bowen D, Culligan D, Jowitt S , et al; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120 (2) 187-200
    CrossrefPubMedGoogle Scholar
  • 22 Pamphilon DH, Aparicio SR, Roberts BE, Menys VC, Tate G, Davies JA. The myelodysplastic syndromes—a study of haemostatic function and platelet ultrastructure. Scand J Haematol 1984; 33 (5) 486-491
    PubMedGoogle Scholar
  • 23 Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2003; 2 (5) 388-394
    PubMedGoogle Scholar
  • 24 Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6 (6) 1301-1314
    PubMedGoogle Scholar
  • 25 DiMinno G, Coraggio F, Cerbone AM , et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77 (1) 157-164
    CrossrefPubMedGoogle Scholar
  • 26 Adams T, Schutz L, Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand J Haematol 1974; 13 (3) 215-224
    PubMedGoogle Scholar
  • 27 Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19 (5) 251-259
    PubMedGoogle Scholar
  • 28 Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 2010; 24 (6) 227-232
    CrossrefPubMedGoogle Scholar
  • 29 Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978; 88 (1) 7-11
    CrossrefPubMedGoogle Scholar
  • 30 Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110 (1) 116-124
    CrossrefPubMedGoogle Scholar
  • 31 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82 (6) 1749-1757
    CrossrefPubMedGoogle Scholar
  • 32 Konkle BA. Acquired disorders of platelet function. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 391-396
    CrossrefPubMedGoogle Scholar
  • 33 Cartoni C, Niscola P, Breccia M , et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma 2009; 50 (3) 387-391
    CrossrefPubMedGoogle Scholar
  • 34 Slats AM, Egeler RM, van der Does-van den Berg A , et al. Causes of death—other than progressive leukemia—in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005; 19 (4) 537-544
    PubMedGoogle Scholar
  • 35 Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 355-364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Franchini M, Veneri D, Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant 2007; 39 (12) 729-735
    CrossrefPubMedGoogle Scholar
  • 37 de la Serna J, Montesinos P, Vellenga E , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111 (7) 3395-3402
    CrossrefPubMedGoogle Scholar
  • 38 Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007; 33 (4) 330-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010; 125 (Suppl. 02) S51-S54
    CrossrefPubMedGoogle Scholar
  • 40 Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16 (3) 463-482
    CrossrefPubMedGoogle Scholar
  • 41 Franchini M, Di Minno MND, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost 2010; 36 (4) 388-403
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Tallman MS, Lefèbvre P, Baine RM , et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2 (8) 1341-1350
    CrossrefPubMedGoogle Scholar
  • 43 Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology (Am Soc Hematol Educ Program) 2007; 151-157
    PubMedGoogle Scholar
  • 44 Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80 (1) 55-63
    CrossrefPubMedGoogle Scholar
  • 45 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395 (1-2) 14-18
    CrossrefPubMedGoogle Scholar
  • 46 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (2) 250-255
    CrossrefPubMedGoogle Scholar
  • 47 Franchini M, Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 806-813
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45 (3) 200-203
    PubMedGoogle Scholar
  • 49 Bossi P, Cabane J, Ninet J , et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105 (5) 400-408
    CrossrefPubMedGoogle Scholar
  • 50 Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81 (10) 768-773
    CrossrefPubMedGoogle Scholar
  • 51 Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91 (6) 1067-1074
    CrossrefPubMedGoogle Scholar
  • 52 Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000; 124 (5) 730-734
    PubMedGoogle Scholar
  • 53 Franchini M, Targher G, Manzato F, Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008; 66 (3) 194-199
    CrossrefPubMedGoogle Scholar
  • 54 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5 (5) 893-900
    CrossrefPubMedGoogle Scholar
  • 56 Franchini M, Sassi M, Dell'Anna P , et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost 2009; 35 (1) 76-80
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121 (1) 21-35
    CrossrefPubMedGoogle Scholar
  • 58 Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63 (1) 47-52
    CrossrefPubMedGoogle Scholar
  • 59 Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor?. Cancer 2012; 118 (2) 312-320
    CrossrefPubMedGoogle Scholar
  • 60 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002; 28 (2) 227-238
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82 (5) 368-375
    CrossrefPubMedGoogle Scholar
  • 62 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Federici AB, Rand JH, Mannucci PM. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J 2001; 2 (6) 358-362
    CrossrefPubMedGoogle Scholar
  • 64 Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?. J Thromb Haemost 2008; 6 (4) 565-568
    CrossrefPubMedGoogle Scholar
  • 65 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (1) (Suppl. 01) S48-S58
    CrossrefPubMedGoogle Scholar
  • 66 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
    CrossrefPubMedGoogle Scholar
  • 67 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92 (8) 2707-2711
    PubMedGoogle Scholar
  • 68 Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32 (1) 45-59
    PubMedGoogle Scholar
  • 69 Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16 (2) 97-110
    CrossrefPubMedGoogle Scholar
  • 70 Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981; 11 (4) 443-450
    CrossrefPubMedGoogle Scholar
  • 71 Comenzo RL. How I treat amyloidosis. Blood 2009; 114 (15) 3147-3157
    CrossrefPubMedGoogle Scholar
  • 72 Choufani EB, Sanchorawala V, Ernst T , et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97 (6) 1885-1887
    CrossrefPubMedGoogle Scholar
  • 73 Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 2004; 41 (1) (Suppl. 01) 93-100
    PubMedGoogle Scholar
  • 74 Bacigalupo A. Haemopoietic stem cell transplants: the impact of hemorrhagic complications. Blood Rev 2003; 17 (Suppl. 01) S6-S10
    CrossrefPubMedGoogle Scholar
  • 75 Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112 (3) 504-510
    CrossrefPubMedGoogle Scholar
  • 76 Pihusch R, Salat C, Schmidt E , et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74 (9) 1303-1309
    CrossrefPubMedGoogle Scholar
  • 77 Pihusch R, Salat C, Göhring P , et al. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br J Haematol 2002; 117 (2) 469-476
    CrossrefPubMedGoogle Scholar
  • 78 Pihusch M, Bacigalupo A, Szer J , et al; F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3 (9) 1935-1944
    CrossrefPubMedGoogle Scholar
  • 79 Kwaan HC. Thrombosis in hematologic malignancies: risk and consequences. Int J Hematol Oncol 2012; 1: 1-9
    CrossrefPubMedGoogle Scholar